Down 8%: What's Behind Teva's Massive Plunge?
Teva Pharmaceuticals is not only one of the biggest generic drug manufacturers in the world but it also sells Copaxone, the branded blockbuster multiple sclerosis treatment. Despite this unique business model, the company has struggled to gain investor confidence over the last few years. It's facing a number of headwinds; the clock on Copaxone's market exclusivity is ticking fast; and new competitors in the multiple sclerosis space, such as Biogen's recently launched drug Tecfidera, are another threat to this drug's sales.
Today, Teva's future is even more uncertain after its CEO announced his resignation. In the following video from The Motley Fool's health-care show, Market Checkup, analyst Max Macaluso discusses the details behind this move and what lies ahead for the company.
An incredible growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article Down 8%: What's Behind Teva's Massive Plunge? originally appeared on Fool.com.
Alison Southwick, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.